



INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH



THE COMPARATIVE OUTCOME OF TOPICAL FORMULATIONS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY IN 125 PATIENTS OF AGE GROUPS 40-60 YEARS:

Muhammad Razi Ullah Khan^{1, 2, 3}, Musaddique Hussain¹, Shahid Masood Raza¹, Saeed Ur Rashid Nazir³, Abrar Ahmed²

¹School of Pharmacy, The University of Faisalabad, Faisalabad, Pakistan.

²Department of Pharmacy, Superior University, Lahore, Pakistan.

³Faculty of Pharmacy, University of Sargodha, Sargodha, Pakistan.

ARTICLE INFO

Article history

Received 17/11/2014

Available online

12/03/2015

Keywords

Cream, Diclofenac,
Etoricoxib,
Piroxicam,
Rheumatoid Arthritis.

ABSTRACT

Non steroidal Anti- inflammatory drugs have their origin as the derivatives of plants, which were observed to have their therapeutic effects in different disease states. Topical delivery of NSAID has its therapeutic applications in management of pain and inflammation in Rheumatoid arthritis patients. The aim of the present investigation was to compare the Etoricoxib cream with Diclofenac and Piroxicam cream in a group of volunteers suffered from Rheumatoid arthritis and to compare the efficacy of these creams in reduction of inflammation. This single blind comparative study was done to determine the efficacy, tolerability and acceptability of topical application of Etoricoxib cream (1% w/w) vs diclofenac cream (1% w/w) and piroxicam cream (0.5% w/w) in Rheumatoid arthritis patients. In this study one hundred and twenty five volunteers suffering with acute Rheumatoid arthritis and age group between 40-60 years were analyzed for assessing the intensity of pain and anti-inflammatory effects of these three creams. The present study revealed that the intensity of pain was lessen up to 98% with Etoricoxib cream, 80% with Diclofenac cream and 84% with piroxicam cream on application of 2 weeks period. Clinically more than 90% improvement was seen in other parameters like tenderness, swelling and functional impairment with Etoricoxib cream as compared to Diclofenac and Piroxicam creams. It had been concluded that at the end of treatment period, Etoricoxib cream was statistically better in reducing pain, tenderness, and swelling and improves the functional ability than Diclofenac cream. Piroxicam cream rated better in these parameter as compared to Diclofenac cream.

Corresponding author

Muhammad Razi Ullah Khan

School of Pharmacy, The University of Faisalabad,

Faisalabad, Pakistan

+92-334-7524323

raziullahpharmacist@gmail.com

Please cite this article in press as **Muhammad Razi Ullah Khan et al.** The Comparative Outcome of Topical Formulations in Rheumatoid Arthritis: A Prospective Study in 125 Patients of Age Groups 40-60 Years. *Indo American Journal of Pharm Research*.2014;4(02).

INTRODUCTION

Rheumatoid arthritis is an autoimmune progressive disorder that leads to the destruction of cartilage, bone and ligaments causing deformity of joints [1]. The cause of rheumatoid arthritis is unknown. It is believed that the tendency to develop rheumatoid arthritis may be genetically inherited (hereditary). Certain genes have been identified that increase the risk for rheumatoid arthritis [2]. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain and inflammation in rheumatoid arthritis patients, but their use comes at the cost of toxicity, with a 2-4% annual incidence of serious gastrointestinal ulcer and complications—four times higher than in non-users [3]. NSAIDs have been applied topically for decades. This route possibly reduces gastrointestinal adverse reactions by maximizing local delivery and minimizing systemic toxicity [4]. Etoricoxib, Diclofenac and Piroxicam are the drugs included in the class of Non-Steroidal Anti-Inflammatory drugs (NSAIDs), each drug has a specific tissue distribution and pharmacodynamics [5]. They block the inflammatory cascade and cyclooxygenases (COX) by inhibiting prostaglandin and thromboxane production and lead to reduction in pain, fever, platelet aggregation and inflammatory response [6]. Besides inhibiting the prostaglandin and thromboxane production, Diclofenac also inhibit rabbit neutrophil and human lung lipoxygenase activity [7]. NSAIDs like Etoricoxib, Diclofenac and Piroxicam are generally indicated for symptomatic relief of Rheumatoid arthritis, Osteoarthritis [8], Inflammatory arthropathies (Ankylosing spondylitis, Psoriatic arthritis), Gout [9], Metastatic bone pain, Post operative pain, Dysmenorrhoea [10], Migraine and Headache. The use of oral preparations of NSAIDs increase the risk of gastrointestinal and cardiovascular complications compared with non NSAIDs users [11]. Reduction of adverse drug reactions associated with the use of topical preparations of NSAIDs is being well considered to obtain high patient compliance and drug therapy efficacy [12].

Substantial data suggests that topical NSAIDs have pain-relieving properties in Rheumatoid Arthritis disease. An important sign of the increasing importance of using topical medication is that the European League against Rheumatism and the International Osteoarthritis Research Society state that topical NSAIDs are preferred over oral NSAIDs for mild-to-moderate hand and knee osteoarthritis, in patients with sensitivity to oral compounds [13]. In addition, the UK NICE guidelines for knee and hand osteoarthritis recommend use of paracetamol and/or topical NSAIDs over oral NSAIDs, COX2 inhibitors, and opioids [14].

MATERIALS AND METHODS:

Human Volunteers:

Total number of volunteers: 125

Gender: Male and Female

Age: 40-60 years

Cream Formulations:

Etoricoxib Cream (1% w/w) [15]

Diclofenac Cream (1% w/w)

Piroxicam Cream (0.5% w/w)

Methods:

This is a single blind, randomized comparative trial conducted at three different locations:

Bajwa Trauma Centre, Sargodha, Pakistan

Aziz Fatima Hospital, Faisalabad, Pakistan

National Hospital, Faisalabad, Pakistan

One hundred and twenty five volunteers were divided into three groups receiving Etoricoxib cream, Diclofenac cream and/or Piroxicam cream. The volunteers were given written instructions to apply the cream regularly on affected area in a dose of 4 inches 3-4 times a day up to 14 days. Volunteers both (males & non-pregnant females) between the ages of 40-60 suffered from Acute Rheumatoid Arthritis were included in this study.

Inclusion Criteria for Study:

- The volunteers were 40-60 years of age
- The volunteer was diagnosed with uncomplicated Acute Rheumatoid arthritis
- The site of injury was accessible to the volunteer so that he/she can apply the study medication himself/herself
- The volunteer must meet the pain entry criteria
- The volunteer was willing to discontinue use of any pain medication not provided as a part of study

Exclusion criteria for study:

- The volunteer has active skin lesions at the intended site of application of study medication. Skin lesions include open wound, rash, papules, vesicles and erythema associated with the site of injury
- The volunteer has used any form of opioids since the time of injury
- The volunteer has taken any form of steroids within 30 days prior to enter into study
- The volunteer has done non-pharmacological treatment of injury
- The volunteer has experienced any kind of allergy to Etoricoxib, Diclofenac or Piroxicam
- The volunteer has participated in an investigational drug study or received an investigational drug within a period of 30 days prior receiving the study medication

Recent injuries sustained within 48 hours (not requiring surgical treatment) were included under "acute" category. Written informed consent was obtained prior to enrollment of patients in the study. The patients were evaluated before initiation of therapy and then at day 1, day 4, day 8 and day 14 of the therapy for the following parameters.

1. Pain:

Onset of pain: pain intensity on a 10cm visual analogue scale (0-worst ever, 10-best ever); pain at rest, passive movement, palpation and isometric contraction on a 4 point scale (0-absent, 1-mild, 2-moderate, 3-severe)

2. Tenderness:

Tenderness on a 4 point scale (0-not tender, 1-tender, 2-wincing, 3-withdrew)

3. Swelling:

Swelling on a 4 point scale (0-absent, 1-mild, 2-moderate, 3-severe)

4. Functional Impairment:

Functional impairment on 5 point scale: (0-none, 1 mild, 2 moderate, 3 marked & 4 severe) Paracetamol was given as rescue drug in case the pain relief by topical formulations was inadequate. The amount of paracetamol intake was recorded as indirect measurement of effectiveness of the trial drugs.

RESULTS AND DISCUSSION:

A total of 125 patients of aged between 40-60 years were enrolled in this study. However 15 patients were lost to follow up and only 110 patients were evaluated. A total of 45 patients received Etoricoxib cream, 35 received Diclofenac cream and 30 received Piroxicam cream. The ratio of males to females in the study was 19:25 (48/62). The patient's demographics of all three groups were comparable.


Table I: Patient Demographics.

Parameters	Etoricoxib Cream	Diclofenac Cream	Piroxicam Cream
Total no. of patients	45	35	30
Sex:			
Male	22	15	11
Female	23	20	19

Within the group all the three groups had improvement in the various parameters studied (onset of pain; pain intensity on a 10 cm VAS; pain at rest, passive movement; palpation and isometric contraction; swelling; tenderness: and functional impairment). This improvement was statistically significant when compared at the beginning and end of the therapy. However, over the study period of 14 days there was no significant change in the paracetamol intake in all the three groups.

The onset of pain relief was observed between 1-2 hours. In some cases the onset of pain relief was quite delayed but there was not much difference between groups. The between group analysis showed that treatment with Etoricoxib cream was significantly more effective than Diclofenac cream and clinically better than Piroxicam cream. The pain intensity on 10cm visual analogue scale was improved upto 9.77 with Etoricoxib cream, 8.01 with Diclofenac cream and 8.44 with piroxicam cream at the end of 14 days therapy. The pain intensity mean score of 9.77cm (when assessed on 0-10 cm VAS) for Etoricoxib cream was statistically more significant ($p < 0.01$) than Diclofenac and Piroxicam cream whose mean scores were 8.01 and 8.44.

On a pain scale comprising of 4 units, pain at rest was reduced up to 0.1 units with Etoricoxib cream, 1.2 with Diclofenac cream and 0.8 with Piroxicam cream at the end of 14 days study period. Pain at passive motion was reduced up to 0.2 with Etoricoxib cream than 0.9 and 0.8 with Diclofenac and Piroxicam groups respectively. Pain at palpitation and isometric contraction was lessened up to 0.5 and 0.6 with Etoricoxib cream group respectively, 1.0 and 1.2 with Diclofenac cream group respectively and 0.9 and 1.0 with Piroxicam cream



Different parameters of Pain

Figure 1: Improvement in Pain over 14 days study period.

Table 1I: Comparative evaluation of different Creams over 14 days period.

Day Characteristics	Etoricoxib Cream (n = 45)				Diclofenac Cream (n = 35)				Piroxicam Cream (n = 30)			
	1	4	8	14	1	4	8	14	1	4	8	14
Pain Intensity on VAS (cm)	4.15	6.29	7.55	9.77	3.75	4.88	6.29	8.01	3.99	5.01	7.0	8.44
Pain at Rest	2.1	1.8	0.7	0.1	2.1	1.9	1.2	0.9	2.1	1.8	1.2	0.8
Pain on passive Motion	2.3	1.9	0.9	0.2	2.3	2.0	1.4	0.9	2.3	1.9	1.3	0.8
Pain on palpation	2.7	2.1	1.2	0.5	2.7	2.2	1.7	1.0	2.7	2.1	1.6	0.9
Pain on Isometric Contraction	3.0	2.4	1.5	0.6	3.0	2.6	1.9	1.2	3.0	2.5	1.6	1.0
Tenderness	2.5	1.8	0.9	0.2	2.5	2.0	1.3	0.8	2.5	1.9	1.1	0.6
Swelling	3.0	2.1	1.4	0.3	3.0	2.4	1.8	1.0	3.0	2.2	1.5	0.8
Functional Impairment	3.5	2.6	1.6	0.5	3.5	2.9	2.0	1.1	3.5	2.8	1.9	0.9

Clinically tenderness was reduced upto 0.2 units in Etoricoxib cream group, 0.8 in Diclofenac cream group and 0.6 in Piroxicam cream group. Absence in swelling was observed 0.3 with Etoricoxib cream group as compared to 1.0 and 0.8 with Diclofenac and Piroxicam group at the end of therapy. Functional improvement was seen 0.5 with Etoricoxib cream group than 1.1 and 0.9 with Diclofenac and Piroxicam cream groups.

No statistically significant difference was observed in the Paracetamol intake between the three groups.

CONCLUSIONS

Etoricoxib, Diclofenac and Piroxicam all three are NSAIDs that exhibit analgesic, antipyretic and anti-inflammatory activities. From the above results it can be concluded that on day 14 Etoricoxib cream was statistically better ($p < 0.01$) in reducing pain, tenderness, and swelling and improves the functional ability than Diclofenac cream. Piroxicam cream rated better ($p < 0.05$) in these parameter as compared to Diclofenac cream.

ACKNOWLEDGEMENTS:

The authors are thankful to Bajwa Trauma Centre Sargodha, Aziz Fatima Hospital Faisalabad and National Hospital Faisalabad, Pakistan for providing necessary facilities and Human volunteers to carryout work with great ease and precision.




Figure II: Improvement in Inflammation over 14 days study period.

REFERENCES

1. Wolfe F, Hawley DJ (1998). The long term outcomes of Rheumatoid Arthritis: Work disability: a prospective 18 year study of 823 patients. *The Journal of Rheumatology*, 25: 2108–2117.
2. Pedersen M, et al. (2007). Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive Rheumatoid Arthritis: a nationwide case-control study in Denmark. *Arthritis and Rheumatology*, 56: 1446–1453.
3. Lanas A (2009). Non-Steroidal Anti-inflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. *American Journal of Medical Sciences*, 338: 96-106.
4. Massó González EL, et al (2010). Variability among Non-Steroidal Anti-inflammatory drugs in risk of upper gastrointestinal bleeding. *Arthritis and Rheumatology*, 62: 1592-1601.
5. Rainsford KD, et al (2008). Review of the pharmaceutical properties and clinical effects of the topical NSAID formulations. *Current Medical Research and Opinion*, 24(10): 2967–2992.
6. Rao P, Knaus EE (2008). Evolution of Non-Steroidal Anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. *Journal of Pharmacy and Pharmaceutical Sciences*, 11(2): 81s–110s.
7. Kokki H, et al (2002). Diffusion of Ketoprofen into the Cerebrospinal Fluid of Young Children. *Pediatric anesthesia*, 12: 313-316.
8. Towheed TE (2006). Pennsaid therapy for Osteoarthritis of the knee: a systematic review and meta analysis of randomized controlled trials. *The Journal of Rheumatology*, 33(3): 567–573.
9. Massey T, et al (2010). Topical NSAIDs for acute pain in adults. *Cochrane Database Systemic Review*, 6: CD007402.
10. Brunton LL, et al (2006). *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 11th edition. New York.
11. Aronson JK, et al (2005). *Meyley's Side Effects of Drugs – The International Encyclopedia of Adverse Drug Reactions and Interactions*, 15th edition. Amsterdam, The Netherlands.
12. Bjorkman DJ (1999). Current Status of Non- Steroidal Anti inflammatory Drugs Use in United States: Risk factors and Frequency of Complications. *American Journal of Medical Sciences*, 107: 35-85.
13. Altman R, Barkin RL (2009). Topical therapy for Osteoarthritis: clinical and pharmacologic perspectives. *Postgraduate Medical Journal*, 121(2): 139–147.
14. Conaghan PG, et al (2008). Guideline Development Group. Care and management of osteoarthritis in adults: summary of NICE guidance. *British Medical Journal*, 336(7642): 502–503.
15. Muhammad Razi Ullah Khan, et al (2014). Formulation Development, Evaluation and Anti-inflammatory effects of Etoricoxib cream. *Indo American Journal of Pharmaceutical Research*, 4(10):3945-3952.



54878478451141139



Submit your next manuscript to **IAJPR** and take advantage of:
 Convenient online manuscript submission
 Access Online first
 Double blind peer review policy
 International recognition
 No space constraints or color figure charges
 Immediate publication on acceptance
 Inclusion in **Scopus** and other full-text repositories
 Redistributing your research freely
 Submit your manuscript at: editorinchief@iajpr.com









